PR Newswire
AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers
📈
AI Sentiment
Highly Positive
8/10
- Home
- ABBV
ABBV
AbbVie Inc.
as of 12-02-2025 2:11pm EST
$223.32
$1.79
-0.80%
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
Chart Type:
Time Range:
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | NORTH CHICAGO |
| Market Cap: | 403.2B | IPO Year: | N/A |
| Target Price: | $240.12 | AVG Volume (30 days): | 6.2M |
| Analyst Decision: | Buy | Number of Analysts: | 18 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 1.32 | EPS Growth: | -53.98 |
| 52 Week Low/High: | $164.39 - $244.81 | Next Earning Date: | 10-31-2025 |
| Revenue: | $59,644,000,000 | Revenue Growth: | 7.40% |
| Revenue Growth (this year): | 10% | Revenue Growth (next year): | 9.17% |
AI-Powered ABBV Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 20 hours ago
AI Recommendation
hold
Model Accuracy: 71.05%
71.05%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Latest AbbVie Inc. News
ABBV Breaking Stock News: Dive into ABBV Ticker-Specific Updates for Smart Investing
MT Newswires
Amneal Pharmaceuticals Wins FDA Approval for Generic Restasis, Plans Q1 Rollout
📊
AI Sentiment
Positive
6/10
GlobeNewswire
Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05%
📈
AI Sentiment
Highly Positive
8/10
Benzinga
If You Invested $10K In AbbVie Stock 10 Years Ago, How Much Would You Have Now?
📈
AI Sentiment
Highly Positive
8/10
Simply Wall St.
AbbVie (NYSE:ABBV) Will Pay A Larger Dividend Than Last Year At $1.73
âž–
AI Sentiment
Neutral
5/10
Motley Fool
3 High-Yielding Dividend Growth Stocks That Can Generate Passive Income for Your Portfolio for Years
📈
AI Sentiment
Highly Positive
8/10
Simply Wall St.
Assessing AbbVie’s (ABBV) Valuation: Is There More Upside After Recent Performance?
📈
AI Sentiment
Highly Positive
8/10
Compare ABBV vs Leading Stocks
See how ABBV stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ABBV AbbVie Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.